全球商业报告（GBR）：2024年美国生命科学行业报告（英文版）（51页）.pdf

《全球商业报告（GBR）：2024年美国生命科学行业报告（英文版）（51页）.pdf》由会员分享，可在线阅读，更多相关《全球商业报告（GBR）：2024年美国生命科学行业报告（英文版）（51页）.pdf（51页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATESLIFE SCIENCES2024Financial Environment-Drug Discovery and Development-HubsRegulation-Contract Manufacturing-AI and New TechnologiesUNITED STATES LIFE SCIENCES 2024GBR SERIESWelcome to the 2024 edition of GBRs United States Life Sciences industry report.Cautious optimism.These two words

2、best describe the state of mind of life sciences executives as we enter the second half of 2024.Having experienced one of its hardest-ever years in 2023 in terms of depressed valuations,public and private fundraising drought,and challenging geopolitical fluctuations the US life sciences industry is

3、now embracing recovery mode.The US remains the leading force in the life sciences industry worldwide,providing an unparalleled ecosystem of VC and institutional investors funding the most promising technologies that emerged out of the brightest minds.From the cloisters of the Ivy League in the East,

4、passing by the shining towers of Wall Street,through the start-up labs of California,and with a flurry of growing hubs across the country,the US remains the premier life sciences hub in the world.Its position as the biggest pharmaceutical market globally attracted an unprecedented number of foreign

5、players in 2023,with Indian CROs,European CDMOs,and South Korean mega-conglomerates establishing a presence there.Yet,big pharma and biotechs face perhaps their biggest challenge to date:That of having to reinvent their business model.Despite a record year for FDA approval(with 55 novel drugs),the r

6、elease in recent years of the anti-obesity GLP-1s,the first ever FDA-approved early-treatment Alzheimers drug,and unprecedented strides in oncology,Big Pharma returns lagged the S&P 500 in the period since the pandemic,and biotech did even worse.Reincorporating risk despite the high chance of failur